Eleni Timotheadou

List of Publications by Year
in descending order

19 papers	275 citations	932766 10 h-index	887659 17 g-index
19 all docs	19 docs citations	19 times ranked	598 citing authors

#	Article	IF	Citations
1	Prophylaxis of cancer‑associated venous thromboembolism with low‑molecular‑weight heparin‑tinzaparin: Real world evidence. Oncology Letters, 2022, 23, 115.	0.8	4
2	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece. Cancers, 2022, 14, 1879.	1.7	3
3	Hereditary Syndromes and Gynaecological Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 22-30.	0.1	0
4	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Current Oncology, 2021, 28, 5266-5277.	0.9	1
5	Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?. Cancers, 2020, 12, 1907.	1.7	5
6	Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental. Anticancer Research, 2020, 40, 305-313.	0.5	8
7	Opposite Prognostic Impact of Single PTEN-loss and *PIK3CA* Mutations in Early High-risk Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 195-206.	1.0	13
8	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer, 2018, 18, 53-62.e3.	1.1	8
9	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine, 2017, 15, 30.	1.8	14
10	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational Oncology, 2017, 10, 589-598.	1.7	17
11	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 2016, 7, 32731-32753.	0.8	30
12	The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. BMC Neurology, 2016, 16, 190.	0.8	21
13	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	1.1	4
14	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. Anticancer Research, 2016, 36, 2365-78.	0.5	6
15	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE, 2015, 10, e0140293.	1.1	29
16	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast, 2014, 23, 234-243.	0.9	26
17	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 2014, 14, 515.	1.1	26
18	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48

#	Article	IF	Citations
19	Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Research, 2007, 27, 4481-9.	0.5	12